Revvity Inc (RVTY)

Currency in USD
150.83
-8.60(-5.39%)
Closed·
150.80-0.03(-0.02%)
·
Advertisement
RVTY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
150.37158.78
52 wk Range
81.22171.74
Key Statistics
Prev. Close
150.83
Open
157.67
Day's Range
150.37-158.78
52 wk Range
81.22-171.74
Volume
2.3M
Average Volume (3m)
1.89M
1-Year Change
68.4875%
Book Value / Share
65.16
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RVTY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
149.87
Downside
-0.64%
Members' Sentiments
Bearish
Bullish
ProTips
Management has been aggressively buying back shares

Revvity Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

6 Buy
11 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 149.87
(-0.64% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy185.00+22.65%175.00Maintain04/11/2026
Bernstein SocGen Group
Hold160.00+6.08%120.00Maintain04/11/2026
RBC Capital
Hold172.00+14.04%135.00Maintain04/11/2026
JPMorgan
Hold160.00+6.08%155.00Maintain04/11/2026
Baird
Buy190.00+25.97%164.00Maintain04/11/2026

Revvity Inc Earnings Call Summary for Q3/2026

  • Revvity reported Q3 2026 adjusted EPS of $1.37 on revenue of $729M, beating estimates of $1.30 and $694.72M; shares surged 8.84% to $165 premarket.
  • Organic growth reached 7% vs. mid-single-digit guidance; life sciences grew 9%, diagnostics 5%, with adjusted operating margin improving to 29.4%.
  • Company raised FY 2026 guidance to ~5% organic growth, $2.86B revenue, and $5.40-$5.45 adjusted EPS, implying 12% YoY growth.
  • CEO Singh highlighted AI-related demand spreading beyond cellular analysis; CFO noted improving conditions since mid-February with strong execution.
  • Q4 guidance projects 5% organic growth, $755M revenue, 32%+ margin, $1.60 EPS; Investor Day on Nov. 13 to discuss 2027 outlook and AI impact.
Last Updated: 03/11/2026, 13:40
Read Full Transcript

Earnings

Latest Release
03/11/2026
EPS / Forecast
1.37 / 1.30
Revenue / Forecast
729M / 694.72M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.26
Dividend Yield
0.19%
Industry Median 1.48%
Annualised payout
0.28
Paid quarterly
5-Years Growth
-
Growth Streak

Compare RVTY to Peers and Sector

Metrics to compare
RVTY
Peers
Sector
Relationship
P/E Ratio
66.6x29.1x−0.2x
PEG Ratio
4.950.710.00
Price/Book
2.3x3.3x2.6x
Price / LTM Sales
5.7x3.4x2.8x
Upside (Analyst Target)
−0.6%−3.6%62.1%
Fair Value Upside
Unlock−0.2%9.5%Unlock

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
75.51M67.67%12.04B
Other Institutional Investors
39.74M32.33%6.34B
Public Companies & Retail Investors
0.000.00%0.00
Total
115.25M100.00%18.37B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
T. Rowe Price Group, Inc.21.03%23,466,0683,741,195
Janus Henderson Group Ltd.7.74%8,637,6141,377,095

People Also Watch

271.34
ESS
-0.07%
85.31
HSIC
-3.32%
15.61
HBAN
-2.80%
26.48
NWSA
-13.35%
20.96
KEY
-2.74%

FAQ

What Is the Revvity (NYSE: RVTY) Share Price Today?

The Revvity stock price today is 150.83 USD.

What Stock Exchange Does Revvity (RVTY) Trade On?

Revvity is listed and trades on the New York Stock Exchange.

What Is the Ticker (Stock Symbol) for Revvity?

The stock symbol (also called a 'ticker') for Revvity is "RVTY."

Does Revvity Pay Dividends? What’s The Current RVTY Dividend Yield?

Yes, RVTY Pays Dividends to its Shareholders. The current Revvity dividend yield is 0.2%%.

What Is the Current Revvity Market Capitalisation?

As of today, Revvity (NYSE: RVTY) market cap is 16.83B USD.

What Is Revvity's (RVTY) Earnings Per Share (TTM)?

The Revvity EPS is currently 2.26 (Trailing Twelve Months).

When Is the Next Revvity Earnings Date?

Revvity's next earnings report will be released on 04/02/2027.

Is RVTY a Buy or Sell From a Technical Analyst Perspective?

Based on today's Revvity moving averages and other technical indicators, the daily buy/sell signal for RVTY stock is Sell.

How Many Times Has Revvity Stock Split?

Revvity has split 4 times. (See the RVTY stock split history page for full effective split date and price information.)

How Many Employees Does Revvity Have?

Revvity has 11000 employees, based on their latest Companies House report.

What is the current trading status of Revvity (NYSE: RVTY)?

As of 06/11/2026, Revvity (RVTY) is trading at a share price of 150.83 USD, with a previous close of 150.83 USD. The stock has fluctuated within a day range of 150.37 USD to 158.78 USD, while its 52-week range spans from 81.22 USD to 171.74 USD.

What Is Revvity (RVTY) Price Target According to Analysts?

The average 12-month price target for Revvity is 149.87 USD, with a high estimate of 185 USD and a low estimate of 110 USD. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -0.64% Downside potential.

What Is the RVTY Premarket Price?

RVTY's last pre-market stock price is 157.42 USD. The pre-market share volume is 11,530.00, and the stock has decreased by -2.01, or -1.26%.

What Is the RVTY After Hours Price?

RVTY's last after hours stock price is 150.80 USD, the stock has decreased by -0.03, or -0.02%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.